New scoring system aims to detect chemo nerve damage earlier
NCT ID NCT07148336
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a simple, self-administered scoring system to identify moderate to severe nerve damage caused by chemotherapy in breast cancer survivors. 26 women who had taxane-based chemotherapy and radiation took part. The goal was to find the best score that separates those with nerve damage from those without, using a symptom-based questionnaire and a neuropathy tracker.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Radiation Oncology, University of Luebeck
Lübeck, Schleswig-Holstein, 23562, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?